Huma, formerly Medopad, is a global digital health technology company that advances digital-first care delivery and research to help people live longer, fuller lives.

Huma's mission to help people with chronic, complex, and rare diseases to live longer, better lives.

Huma was founded in 2011 by Dan Vahdat and Rich Khatib. The company is headquartered in London, UK, with offices in New York, Shanghai and Hamburg.

Huma's modular platform supports digital 'hospitals at home' across different disease areas. The platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive, predictive care and research.

Huma's 'hospitals at home' help care for patients across the England NHS, Wales, Germany, and the UAE — evidence shows they can double clinical capacity, reduce readmission rates by a third, and reduce costs whilst providing safe, high-quality care.

Huma works with leading life science companies including AstraZeneca, Bayer and Janssen and academic institutions such as Stanford Medicine, the Johns Hopkins Bloomberg School of Public Health and the University of Cambridge. Huma's platform is trusted by more than 3,000 hospitals and clinics, with 1.8 million active users.

Huma is backed by Leaps by Bayer, Hitachi Ventures, AstraZeneca, NWS Holding, Healthbox, Bupa, Sony Innovation Fund, Unilever Ventures, Samsung NEXT, HAT Technology & Innovation Fund, and others. The company raised £25M ($33M) in new financing on Mar 23, 2022. This brings Huma's total funding to $217M to date.